Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Douglas Schlichting
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND
Abstract Objective To evaluate the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active rheumatoid arthritis (RA). Methods Patients completed 1 of 3 phase III baricitinib trials (ClinicalTrials.gov: NCT01711359, NCT01710358, or NCT01721057) and entered the long-term extension RA-BEYOND (NCT01885078), in which patients received once-daily 4 mg or 2 mg baricitinib.
Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND
From Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; Eli Lilly and Company, Indianapolis United States; UCL-Saint Luc, Brussels, Belgium; The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; Metroplex Clinical Research Center/University of Texas Southwestern Medical Center, Dallas, United States Financial support for the studies was provided by Eli Lilly and Company, which developed baricitinib,...
Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
Correction to: Arthritis Research & Therapy (2020) 22: 115 https://doi.org/10.1186/s13075-020-02199-8 Following publication of the original article [1], the authors identified errors in Fig. 1. The legends in Fig. 1c and d refer to placebo, baricitinib 4-mg and adalimumab treatment groups; the legends should refer to placebo, baricitinib 2-mg, and baricitinib 4-mg and the reference to these two studies in the figure caption are reversed.
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
Abstract Background In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of baricitinib and placebo-matched tablets in phase 3 studies of patients with moderate-to-severe rheumatoid arthritis (RA) and describe their impact on efficacy and safety.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Douglas
Contact Douglas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack